Liminatus Pharma (LIMN) Income from Continuing Operations (2024 - 2026)
Liminatus Pharma (LIMN) posted Income from Continuing Operations of 1119536.0 for Q1 2026, down 56.88% sequentially from 713610.0 in Q4 2025, and down 241.82% YoY from 789429.02 in Q1 2025.
Liminatus Pharma (LIMN) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Income from Continuing Operations for 3 years, with the latest figure at 1119536.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 241.82% year-over-year to 1119536.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3709484.0 (down 63.17% YoY) and the FY2025 annual result came in at 5236996.0, down 47.67% from the prior year.
- Income from Continuing Operations fell to 1119536.0 in Q1 2026 per LIMN's latest filing, from 713610.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 327526.0 in Q1 2025 and troughed at 1156116.0 in Q2 2025.
- A 3-year average of 747850.62 and a median of 716916.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations decreased 19.76% in 2025, then plunged 241.82% in 2026.
- Over 3 years, Income from Continuing Operations stood at 383216.0 in 2024, then slumped by 86.22% to 713610.0 in 2025, then sank by 56.88% to 1119536.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1119536.0, 713610.0, and 720222.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | -1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.12 Mn |
| Dec 31, 2025 | -713,610.00 |
| Sep 30, 2025 | -720,222.00 |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | -327,526.00 |
| Dec 31, 2024 | -383,216.00 |
| Sep 30, 2024 | -601,372.00 |
| Jun 30, 2024 | -961,207.00 |